Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.77 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.72 |
| ▸ | MMP9 | P14780 | 1/20 | 0.67 |
| ▸ | BACE1 | P56817 | 3/20 | 0.61 |
| ▸ | MAOB | P27338 | 4/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.60 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598938 | 1.00 | MMP8 (0.77) | MMP8HSD17B3MMP9BACE1MAOB | |
| SCHEMBL3222739 | 0.93 | MAOB (0.73) | MMP8HSD17B3MMP9BACE1MAOB | |
| SCHEMBL3222733 | 0.93 | MAOB (0.73) | MMP8HSD17B3MMP9BACE1MAOB | |
| SCHEMBL24687567 | 0.93 | HSD17B3 (0.69) | MMP8HSD17B3MMP9BACE1MAOB | |
| SCHEMBL11741168 | 0.90 | MMP9 (0.65) | MMP8HSD17B3MMP9BACE1MAOB | |
| SCHEMBL24687571 | 0.90 | MMP8 (0.65) | MMP8HSD17B3MMP9BACE1MAOB | |
| SCHEMBL11142134 | 0.89 | HSD17B3 (0.68) | MMP8HSD17B3MMP9BACE1MAOB | |
| SCHEMBL11142130 | 0.89 | HSD17B3 (0.68) | MMP8HSD17B3MMP9BACE1MAOB | |
| SCHEMBL10077705 | 0.87 | MMP8 (1.00) | MMP8HSD17B3MMP9BACE1MAOB | |
| SCHEMBL6228550 | 0.87 | MMP8 (0.62) | MMP8HSD17B3MMP9BACE1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265041-A1 | CURCUMIN ANALOGUES AS ZINC CHELATORS AND TEHIR USES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-08-24 | — | — | US | disclosed |
| US-11714354-B2 | Lithographic printing plate precursor and method of use | EASTMAN KODAK COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-11714354-B2 | Lithographic printing plate precursor and method of use | EASTMAN KODAK COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20210302834-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR AND METHOD OF USE | BANK OF AMERICA, N.A., AS AGENT | 2021-09-30 | — | — | US | disclosed |
| US-20160213638-A1 | POLYENOLIC ZINC-BINDING AGENTS (PEZBINS) ACTIVELY PROMOTE INACTIVATION OF CANCER STEM CELLS AND POTENTIATE CYTOTOXIC ANTI-TUMOR DRUG SUBSTANCES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC UNM (US) | 2016-02-11 | — | — | US | disclosed |
| US-9187397-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150073021-A1 | CHEMICALLY MODIFIED CURCUMINS AS INHIBITORS OF ANTHRAX LETHAL FACTOR | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213638-A1 | POLYENOLIC ZINC-BINDING AGENTS (PEZBINS) ACTIVELY PROMOTE INACTIVATION OF CANCER STEM CELLS AND POTENTIATE CYTOTOXIC ANTI-TUMOR DRUG SUBSTANCES | BAZ2B, CEBPZ, BAZ2A | MMP8 3046/4885HSD17B3 1823/4885MMP9 1634/4885 |
| US-20150073021-A1 | CHEMICALLY MODIFIED CURCUMINS AS INHIBITORS OF ANTHRAX LETHAL FACTOR | ANTXR2, APAF1, LITAF | MMP8 248/4885HSD17B3 4752/4885MMP9 1104/4885 |
| US-20230265041-A1 | CURCUMIN ANALOGUES AS ZINC CHELATORS AND TEHIR USES | NFRKB, NFKBIA, NFKB1 | MMP8 34/4885HSD17B3 3358/4885MMP9 17/4885 |
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | MMP8 221/4885HSD17B3 1637/4885MMP9 1372/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | MMP8 221/4885HSD17B3 1637/4885MMP9 1372/4885 |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | MMP8 221/4885HSD17B3 1637/4885MMP9 1372/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | MMP8 710/4885HSD17B3 881/4885MMP9 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.